Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis: a retrospective study

World Journal of Surgical Oncology

Ou-Chen Wang¹  Xiao-Hua Zhang¹  Gui-Long Guo¹  Han Yang¹  Wei Zhang¹  Er-li Gao¹  Yi-Li Zhou¹ 

[1] Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, No.2 Fuxue lane, Wenzhou, Zhejiang, China

关键词: Central lymph node metastasis;    Thyroidectomy;    Multifocality;    Bilateral thyroid cancer;    Papillary micro-carcinoma;   

Others  :  827840
DOI  :  10.1186/1477-7819-10-67

 received in 2012-02-01, accepted in 2012-04-27,  发布年份 2012

【 摘 要 】

Background

The optimal resection extent for papillary thyroid microcarcinoma (PTMC) remains controversial. The objective of the study was to investigate risk factors of bilateral PTMC and central lymph node metastasis (CLNM) to guide surgical strategies for PTMC patients.

Methods

We retrospectively reviewed 211 PTMC patients who underwent total thyroidectomy (TT) and 122 clinical lymph node-negative (cN0) cases that underwent prophylactic central lymph node dissection (CLND) between 2010 and 2011. The frequency, pattern, and predictive factors for bilateral PTMC and CLNM in these patients were studied using univariate and multivariate analysis with respect to the following variables: age, gender, extrathyroidal extension (ETE), T stage, with Hashimoto thyroiditis (HT), tumor size and multifocality based on final pathology, and preoperative evaluation using ultrasonography (US).

Results

Fifty-four of 211 (25.6%) patients had bilateral PTMC. In multivariate analysis, multifocality (P < 0.001, OR = 23.900) and tumor size ≥7 mm (P = 0.014, OR = 2.398) based on US were independent predictive factors for bilateral PTMC which was also independently associated with multifocality (P < 0.001, OR = 29.657) and tumor size ≥7 mm (P = 0.005, OR = 2.863) based on final pathology. Among 122 cN0 patients who underwent prophylactic CLND, we found 49.2% of patients had CLNM. CLNM was independently associated with men, age <50 years and tumor size ≥7 mm based on final pathology or preoperative US.

Conclusions

TT should be considered for PTMC patients who are found multifocality and tumor size ≥7 mm based on preoperative US. CLND need be considered in cN0 patients who are men, aged <50 years or tumor size ≥7 mm based on preoperative US.

【 授权许可】

   
2012 zhou et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Sherman SI: Thyroid carcinoma. Lancet 2003, 361:501-511.
• [2]Zheng W, Zhang Z: An analysis of cancer incidence in 2005 in Lucheng District, Wenzhou City, Zhejiang Province. Bull Chin Cancer 2007, 16:306-308.
• [3]Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167.
• [4]Shindo M, Wu JC, Park EE, Tanzella F: The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2006, 132:650-654.
• [5]Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A: An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003, 13:381-387.
• [6]Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, Cailleux AF, Lumbroso JD, Parmentier C, Schlumberger M: Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998, 83:553-559.
• [7]Noguchi S, Yamashita H, Murakami N, Nakayama I, Toda M, Kawamoto H: Small carcinomas of the thyroid. A long-term follow-up of 867 patients. Arch Surg 1996, 131:187-191.
• [8]Hay ID, Grant CS, Taylor WF, McConahey WM: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987, 102:1088-1095.
• [9]Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ, Goellner JR: Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008, 144:980-987. discussion 987–988
• [10]Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, Gardini G, Valcavi R, Barbieri V: Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009, 19:707-716.
• [11]Jacquot-Laperriere S, Timoshenko AP, Dumollard JM, Peoc’h M, Estour B, Martin C, Prades JM: Papillary thyroid microcarcinoma: incidence and prognostic factors. Eur Arch Otorhinolaryngol 2007, 264:935-939.
• [12]Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y: Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003, 237:399-407.
• [13]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142.
• [14]Pasieka JL, Thompson NW, McLeod MK, Burney RE, Macha M: The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 1992, 16:711-716. discussion 716–717
• [15]Pitt SC, Sippel RS, Chen H: Contralateral papillary thyroid cancer: does size matter? Am J Surg 2009, 197:342-347.
• [16]Wang W, Zhao W, Wang H, Teng X, Chen X, Li Z, Yu X, Fahey TJ, Teng L: Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 2012, 19:31-36.
• [17]Schonberger J, Marienhagen J, Agha A, Rozeboom S, Bachmeier E, Schlitt H, Eilles C: Papillary microcarcinoma and papillary cancer of the thyroid < or = 1 cm: modified definition of the WHO and the therapeutic dilemma. Nuklearmedizin 2007, 46:115-120. quiz N141–112
• [18]Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH: Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003, 98:31-40.
• [19]Kim ES, Kim TY, Koh JM, Kim YI, Hong SJ, Kim WB, Shong YK: Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf) 2004, 61:145-148.
• [20]Koo BS, Lim HS, Lim YC, Yoon YH, Kim YM, Park YH, Rha KS: Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Ann Surg Oncol 2010, 17:1101-1105.
• [21]Wang W, Wang H, Teng X, Mao C, Teng R, Zhao W, Cao J, Fahey TJ, Teng L: Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Hum Pathol 2010, 41:1299-1309.
• [22]Connor MP, Wells D, Schmalbach CE: Variables predictive of bilateral occult papillary microcarcinoma following total thyroidectomy. Otolaryngol Head Neck Surg 2011, 144:210-215.
• [23]Hwang E, Pakdaman MN, Tamilia M, Hier MP, Black MJ, Rochon L, Payne RJ: Bilateral papillary thyroid cancer and associated histopathologic findings. J Otolaryngol Head Neck Surg 2010, 39:284-287.
• [24]Hwang E, Pakdaman MN, Black MJ, Payne RJ: Tumour size and bilateral thyroid cancer after thyroidectomy. Otolaryngol Head Neck Surg 2008, 139:P47.
• [25]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
• [26]Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK: Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 2009, 193:871-878.
• [27]Kwak JY, Kim EK, Kim MJ, Son EJ, Chung WY, Park CS, Nam KH: Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol 2009, 16:1348-1355.
• [28]So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung MK: Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery 2010, 148:526-531.
• [29]Roh JL, Kim JM, Park CI: Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol 2008, 15:2482-2486.
• [30]Lin JD, Chen ST, Chao TC, Hsueh C, Weng HF: Diagnosis and therapeutic strategy for papillary thyroid microcarcinoma. Arch Surg 2005, 140:940-945.
• [31]Ji QH, Zhang L, Zhu YX, Huang CP: Long-term impact of initial surgical and medical therapy on young patients with papillary thyroid cancer and bilateral cervical metastases. Chin Med J (Engl) 2008, 121:63-66.
• [32]Lee SH, Lee SS, Jin SM, Kim JH, Rho YS: Predictive factors for central compartment lymph node metastasis in thyroid papillary microcarcinoma. Laryngoscope 2008, 118:659-662.
• [33]Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, Pearce EN, Braverman LE, Degli Uberti EC: Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006, 91:2171-2178.
• [34]Lee KJ, Cho YJ, Kim SJ, Lee SC, Kim JG, Ahn CJ, Lee DH: Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg 2011, 35:318-323.